Poolbeg Pharma in-licencing exciting programmes ready for big pharma (Interview)

Poolbeg Pharma plc (LON:POLB) CEO Jeremy Skillington joins DirectorsTalk Interviews to discuss the in-licencing of a novel, first-in-class RNA-based immunotherapy for respiratory virus infections.

Jeremy tells us more about this new deal, explains the terms, what being at a late pre-clinical stage means and explains the ultimate plan for this asset.

Poolbeg Pharma (LON: POLB) is a clinical stage infectious disease pharmaceutical company, with a clinical model which enables them to develop multiple products faster and more cost effectively than a traditional biotech model.

You might also enjoy reading  Poolbeg Pharma OneThree Biotech completes build and optimisation of RSV AI model
Find more news, interviews, share price & company profile here for:
Poolbeg Pharma plc

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Poolbeg Pharma in-licencing exciting programmes ready for big pharma (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions